Juan Jesús
Cruz Hernández
Profesor Emérito
Institut d'Investigació Biomédica de Bellvitge
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institut d'Investigació Biomédica de Bellvitge (2)
2022
2017
-
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study
International Journal of Radiation Oncology Biology Physics, Vol. 97, Núm. 3, pp. 473-480